Physician profile
Ryan Doster
NPI 1285868877
$1,535.41
in general payments reported to CMS, 2019-2025
11 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $159 · 2023: $665 · 2024: $526 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.45 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $471.64 | 2022-2025 | Cresemba |
| Merck Sharp & Dohme LLC | $195.65 | 2022-2024 | Dificid, Recarbrio, Zerbaxa |
| Insmed, INC. | $180.95 | 2023-2025 | Arikayce |
| Abbvie INC. | $143.90 | 2022-2025 | Avycaz, Dalvance, Teflaro |
| Shionogi INC | $140.39 | 2023-2025 | Fetroja |
| Gilead Sciences, INC. | $136.26 | 2022-2024 | |
| Pfizer INC. | $135.56 | 2023-2025 | |
| Melinta Therapeutics, LLC | $46.76 | 2022-2023 | Orbactiv, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $45.55 | 2023-2024 | Nuzyra |
| Novavax INC | $23.42 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Oxford Immunotec USA INC | $15.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Doster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.